Omega Therapeutics is a clinical-stage biotechnology company focused on developing a new class of precision genetic medicines through its proprietary ECHELON™ platform. Headquartered in Boston, Massachusetts, the company applies programmable epigenetic control to selectively turn genes on or off, aiming to provide durable treatments for rare diseases, oncology and immunological disorders. Omega’s approach leverages synthetic DNA sequences to reprogram gene expression without permanently altering the genomic code.
The ECHELON platform centers on synthetic cis-regulatory elements that guide endogenous cellular machinery to modulate target genes with spatial and temporal specificity. By combining computational design, high-throughput screening and advanced delivery technologies, Omega seeks to address previously undruggable targets. Its preclinical pipeline encompasses programs in rare neuromuscular diseases, solid tumors and autoimmune conditions, with collaboration agreements supporting clinical translation.
Founded in 2019 by a team of researchers with backgrounds in genetics, molecular biology and drug development, Omega Therapeutics has expanded its operations to include laboratories in both North America and Europe. The company maintains partnerships with academic institutions and biopharma organizations to accelerate R&D efforts, while investing in scalable manufacturing capabilities to support future clinical and commercial needs.
Omega’s leadership team combines seasoned executives from leading biotechnology and pharmaceutical firms with academic pioneers in gene regulation. The company’s management brings deep expertise in translational medicine, regulatory strategy and commercial development, supported by a scientific advisory board drawn from top-tier research institutions.
AI Generated. May Contain Errors.
Free OMGAQ Stock Alerts